Fred Alger Management LLC Increases Stock Holdings in Adaptive Biotechnologies Corporation $ADPT

Fred Alger Management LLC increased its stake in shares of Adaptive Biotechnologies Corporation (NASDAQ:ADPT) by 6.7% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,514,234 shares of the company’s stock after buying an additional 158,807 shares during the quarter. Fred Alger Management LLC’s holdings in Adaptive Biotechnologies were worth $37,613,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also bought and sold shares of ADPT. XTX Topco Ltd purchased a new position in Adaptive Biotechnologies during the 2nd quarter worth $793,000. SG Americas Securities LLC raised its holdings in shares of Adaptive Biotechnologies by 53.2% in the second quarter. SG Americas Securities LLC now owns 37,328 shares of the company’s stock valued at $435,000 after purchasing an additional 12,963 shares during the last quarter. Allianz Asset Management GmbH raised its holdings in shares of Adaptive Biotechnologies by 305.8% in the third quarter. Allianz Asset Management GmbH now owns 321,774 shares of the company’s stock valued at $4,814,000 after purchasing an additional 242,474 shares during the last quarter. Hillsdale Investment Management Inc. bought a new position in shares of Adaptive Biotechnologies during the second quarter valued at about $6,618,000. Finally, Envestnet Asset Management Inc. bought a new position in shares of Adaptive Biotechnologies during the second quarter valued at about $467,000. 99.17% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Adaptive Biotechnologies

In related news, insider Susan Bobulsky sold 41,338 shares of the company’s stock in a transaction that occurred on Wednesday, March 11th. The stock was sold at an average price of $13.17, for a total value of $544,421.46. Following the transaction, the insider owned 427,775 shares in the company, valued at approximately $5,633,796.75. This represents a 8.81% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Kyle Piskel sold 18,672 shares of the stock in a transaction on Wednesday, March 11th. The shares were sold at an average price of $13.17, for a total value of $245,910.24. Following the transaction, the chief financial officer directly owned 259,840 shares of the company’s stock, valued at approximately $3,422,092.80. This trade represents a 6.70% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 2,350,698 shares of company stock worth $34,449,277 over the last 90 days. Corporate insiders own 6.40% of the company’s stock.

Adaptive Biotechnologies Stock Performance

ADPT opened at $13.17 on Monday. The firm has a market cap of $2.03 billion, a P/E ratio of -32.92 and a beta of 2.19. The firm has a 50-day moving average of $16.55 and a 200 day moving average of $15.89. Adaptive Biotechnologies Corporation has a fifty-two week low of $6.68 and a fifty-two week high of $20.76.

Adaptive Biotechnologies (NASDAQ:ADPT) last posted its quarterly earnings data on Thursday, February 5th. The company reported ($0.09) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.10. The business had revenue of $71.68 million during the quarter, compared to the consensus estimate of $59.38 million. Adaptive Biotechnologies had a negative net margin of 21.48% and a negative return on equity of 46.68%. The firm’s quarterly revenue was up 51.0% compared to the same quarter last year. During the same quarter last year, the company posted ($0.23) earnings per share. Equities research analysts predict that Adaptive Biotechnologies Corporation will post -0.92 earnings per share for the current fiscal year.

Adaptive Biotechnologies News Summary

Here are the key news stories impacting Adaptive Biotechnologies this week:

• Positive Sentiment: Recent fundamental backdrop: Adaptive’s Feb. 5 quarterly report showed an EPS beat and revenue that was up ~51% year-over-year, supporting investor confidence heading into March. MarketBeat ADPT profile
• Neutral Sentiment: Short-interest print for March shows 0 shares and NaN changes (likely a reporting error). That data point provides no clear bearish signal and may have contributed to lower perceived short pressure. (No reliable short-interest signal.)
• Negative Sentiment: Significant insider selling on Mar. 11–13: combined, company executives and insiders sold roughly 1.25M shares for about $16.6M in proceeds, materially reducing several insiders’ stakes (examples below). This coordinated selling can be perceived negatively by investors as supply into the market or insiders taking liquidity. Filings: CEO Chad M. Robins (470,167 sh, ~$6.19M) Chad Robins Form 4; Harlan S. Robins (470,266 sh, ~$6.19M) Harlan Robins Form 4; COO Julie Rubinstein (160,643 sh across filings) Julie Rubinstein Form 4; CFO Kyle Piskel (18,672 sh) Kyle Piskel Form 4; Sharon Benzeno (63,103 sh) Sharon Benzeno Form 4; Susan Bobulsky (41,338 sh) Susan Bobulsky Form 4; Francis Lo (30,593 sh) Francis Lo Form 4.

Wall Street Analyst Weigh In

ADPT has been the subject of a number of recent analyst reports. Wall Street Zen downgraded shares of Adaptive Biotechnologies from a “buy” rating to a “hold” rating in a research report on Saturday, March 7th. Weiss Ratings reissued a “sell (d-)” rating on shares of Adaptive Biotechnologies in a research report on Wednesday, January 21st. Piper Sandler set a $21.00 target price on Adaptive Biotechnologies in a research note on Friday, February 6th. TD Cowen reaffirmed a “buy” rating on shares of Adaptive Biotechnologies in a report on Friday, February 6th. Finally, Morgan Stanley started coverage on Adaptive Biotechnologies in a research report on Monday, December 1st. They set an “equal weight” rating and a $21.00 price target for the company. Seven equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $18.25.

About Adaptive Biotechnologies

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.